{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:58:03Z","timestamp":1767992283859,"version":"3.49.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.prp.2026.156351","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:33:45Z","timestamp":1767598425000},"page":"156351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Overcoming barriers in cancer therapy with oncolytic adenoviruses: Engineering strategies and clinical perspectives"],"prefix":"10.1016","volume":"278","author":[{"given":"Rohit","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh Kumar","family":"Chellappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3722-991X","authenticated-orcid":false,"given":"Poonam","family":"Negi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"key":"10.1016\/j.prp.2026.156351_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2024.112800","article-title":"Carbon nanotube-mediated platinum-based drug delivery for the treatment of cancer: advancements and future perspectives","volume":"206","author":"Sameer Khan","year":"2024","journal-title":"Eur. Polym. J."},{"issue":"21","key":"10.1016\/j.prp.2026.156351_bib3","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/cncr.35458","article-title":"Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates","volume":"130","author":"Bizuayehu","year":"2024","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.prp.2026.156351_bib4","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.3390\/cancers14133272","article-title":"Liquid biopsy in prostate cancer management-current challenges and future perspectives","volume":"14","author":"Crocetto","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.prp.2026.156351_bib5","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2026.156351_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155652","article-title":"Targeting the p53-p21 axis in liver cancer: Linking cellular senescence to tumor suppression and progression","volume":"263","author":"Thangavelu","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"19","key":"10.1016\/j.prp.2026.156351_bib7","doi-asserted-by":"crossref","first-page":"11363","DOI":"10.3390\/ijms231911363","article-title":"Challenges and future trends of hepatocellular carcinoma immunotherapy","volume":"23","author":"Rizzo","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156351_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4161\/cbt.4.5.1820","article-title":"Viral oncolysis by herpes simplex virus and other viruses","volume":"4","author":"Kuruppu","year":"2005","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.prp.2026.156351_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/or.2021.8000","article-title":"Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review)","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/08830185.2013.823420","article-title":"Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection","volume":"33","author":"Chen","year":"2014","journal-title":"Int. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.prp.2026.156351_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.prp.2026.156351_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2004.15.1022","article-title":"Biology of adenovirus and its use as a vector for gene therapy","volume":"15","author":"McConnell","year":"2004","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.prp.2026.156351_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers12051139","article-title":"Expanding the spectrum of adenoviral vectors for cancer therapy","volume":"12","author":"Gao","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QCO.0000000000000451","article-title":"Human adenovirus infections: update and consideration of mechanisms of viral persistence","volume":"31","author":"Radke","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.prp.2026.156351_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100826","article-title":"Mystery eye: human adenovirus and the enigma of epidemic keratoconjunctivitis","volume":"76","author":"Jonas","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"issue":"24","key":"10.1016\/j.prp.2026.156351_bib16","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1002\/1873-3468.13693","article-title":"Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D","volume":"593","author":"Ismail","year":"2019","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-019-08599-y","article-title":"Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions","volume":"10","author":"Baker","year":"2019","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.prp.2026.156351_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02487-16","article-title":"Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum","volume":"91","author":"Lopez-Gordo","year":"2017","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.virol.2009.07.010","article-title":"Defining the role of CD46, CD80 and CD86 in mediating adenovirus type 3 fiber interactions with host cells","volume":"392","author":"Hall","year":"2009","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.prp.2026.156351_bib20","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.3390\/cancers12113327","article-title":"Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies","volume":"12","author":"Cunliffe","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00390-18","article-title":"Hacking the Cell: network intrusion and exploitation by adenovirus E1A","volume":"9","author":"King","year":"2018","journal-title":"mBio"},{"issue":"31","key":"10.1016\/j.prp.2026.156351_bib22","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.vaccine.2009.03.074","article-title":"In situ adenovirus vaccination engages T effector cells against cancer","volume":"27","author":"Tuve","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1074377","article-title":"A century of oncolysis evolves into oncolytic immunotherapy","volume":"5","author":"Hemminki","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/viro.1997.8597","article-title":"Cloning and Sequencing of the Cellular\u2013Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line","volume":"233","author":"Louis","year":"1997","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.prp.2026.156351_bib25","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.3390\/cimb45060307","article-title":"Adenovirus as a Vector and Oncolytic Virus","volume":"45","author":"Matsunaga","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"24","key":"10.1016\/j.prp.2026.156351_bib26","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/1873-3468.13682","article-title":"Immune evasion by adenoviruses: a window into host\u2013virus adaptation","volume":"593","author":"Oliveira","year":"2019","journal-title":"FEBS Lett."},{"issue":"6","key":"10.1016\/j.prp.2026.156351_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00370-23","article-title":"Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication","volume":"97","author":"Ehrenfeld","year":"2023","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","article-title":"Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications","volume":"132","author":"Hartman","year":"2008","journal-title":"Virus Res."},{"issue":"7","key":"10.1016\/j.prp.2026.156351_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181012","article-title":"Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells","volume":"12","author":"Saha","year":"2017","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.prp.2026.156351_bib30","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1128\/JVI.77.9.5295-5304.2003","article-title":"Distinct Roles of the Adenovirus E4 ORF3 Protein in Viral DNA Replication and Inhibition of Genome Concatenation","volume":"77","author":"Evans","year":"2003","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.97.3.1002","article-title":"Optimization of the helper-dependent adenovirus system for production and potency in vivo","volume":"97","author":"Sandig","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"issue":"9","key":"10.1016\/j.prp.2026.156351_bib33","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.3390\/ijms24097736","article-title":"Viral vector-based gene therapy","volume":"24","author":"Li","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.prp.2026.156351_bib34","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.3390\/ijms24097736","article-title":"Viral vector-based gene therapy","volume":"24","author":"Li","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.prp.2026.156351_bib35","first-page":"1","article-title":"No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"10.1016\/j.prp.2026.156351_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"BioTechniques"},{"issue":"22","key":"10.1016\/j.prp.2026.156351_bib37","doi-asserted-by":"crossref","first-page":"16519","DOI":"10.3390\/ijms242216519","article-title":"Adenoviral gene therapy vectors in clinical use\u2014basic aspects with a special reference to replication-competent adenovirus formation and its impact on clinical safety","volume":"24","author":"Leikas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156351_bib38","first-page":"2021","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.prp.2026.156351_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"6","key":"10.1016\/j.prp.2026.156351_bib40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/sj.emboj.7600597","article-title":"Adenoviral proteins mimic nutrient\/growth signals to activate the mTOR pathway for viral replication","volume":"24","author":"O'Shea","year":"2005","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.prp.2026.156351_bib42","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1128\/JVI.01972-08","article-title":"E4orf1 Limits the Oncolytic Potential of the E1B-55K Deletion Mutant Adenovirus","volume":"83","author":"Thomas","year":"2009","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.prp.2026.156351_bib43","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2026.156351_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2026.156351_bib45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jconrel.2017.11.036","article-title":"Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates","volume":"269","author":"Abdelaziz","year":"2018","journal-title":"J. Control. Release"},{"issue":"16","key":"10.1016\/j.prp.2026.156351_bib46","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-22-3699","article-title":"FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC","volume":"29","author":"Mathieu","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/ijms23031853","article-title":"Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer","volume":"23","author":"Haider","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156351_bib48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2015.10.019","article-title":"Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo","volume":"487","author":"Gomez-Gutierrez","year":"2016","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.prp.2026.156351_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14737159.2025.2464563","article-title":"Decoding pancreatic cancer: key risk factors across genetics and lifestyle","volume":"25","author":"Sharma","year":"2025","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.prp.2026.156351_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216456","article-title":"Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?","volume":"579","author":"Yoon","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156351_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145766","article-title":"Exosome-mediated communication in pancreatic cancer: From molecular crosstalk to clinical translation","volume":"320","author":"Khan","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2026.156351_bib52","first-page":"1","article-title":"Comprehensive insights into pancreatic cancer treatment approaches and cutting-edge nanocarrier solutions: from pathology to nanomedicine","author":"Sharma","year":"2025","journal-title":"NaunynSchmiede 's. Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.14701\/ahbps.2021.25.3.315","article-title":"Mutations of p53 associated with pancreatic cancer and therapeutic implications","volume":"25","author":"Voutsadakis","year":"2021","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"issue":"14","key":"10.1016\/j.prp.2026.156351_bib55","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","article-title":"A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression","volume":"48","author":"Yamasaki","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2026.156351_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omto.2020.03.016","article-title":"Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer","volume":"17","author":"Koujima","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00262-024-03849-5","article-title":"Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity","volume":"74","author":"Ohtani","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156351_bib58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.prp.2026.156351_bib59","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12985-024-02286-1","article-title":"Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma","volume":"21","author":"Hadi","year":"2024","journal-title":"Virol. J."},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/CAD.0000000000000854","article-title":"A dual cancer-specific recombinant adenovirus suppresses the growth of liver cancer cells in vivo and in vitro","volume":"31","author":"Tian","year":"2020","journal-title":"AntiCancer Drugs"},{"issue":"20","key":"10.1016\/j.prp.2026.156351_bib62","doi-asserted-by":"crossref","first-page":"18201","DOI":"10.1007\/s00432-023-05501-8","article-title":"Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune response in liver cancer","volume":"149","author":"Qiang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2026.156351_bib63","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ymthe.2023.04.006","article-title":"Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial","volume":"31","author":"Heo","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2026.156351_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154319","article-title":"Renal clear cell carcinoma-derived CXCL5 drives tumor-associated fibroblast formation and facilitates cancer progression","volume":"244","author":"Liu","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"10","key":"10.1016\/j.prp.2026.156351_bib65","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1089\/end.2017.0382","article-title":"Renal Cell Carcinoma: Alternative Nephron-Sparing Treatment Options for Small Renal Masses, a Systematic Review","volume":"31","author":"Prins","year":"2017","journal-title":"J. Endourol."},{"issue":"10","key":"10.1016\/j.prp.2026.156351_bib66","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1535-7163.MCT-07-0176","article-title":"Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses","volume":"6","author":"Guse","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2026.156351_bib67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2021.11.018","article-title":"Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma","volume":"24","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"18","key":"10.1016\/j.prp.2026.156351_bib68","doi-asserted-by":"crossref","first-page":"10744","DOI":"10.1111\/jcmm.15697","article-title":"Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer","volume":"24","author":"Chai","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/cgt.2008.61","article-title":"Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA","volume":"16","author":"Zheng","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.prp.2026.156351_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155607","article-title":"A review on tyrosine kinase inhibitors for targeted breast cancer therapy","volume":"263","author":"Sankarapandian","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2026.156351_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216634","article-title":"Oncolytic virus-based combination therapy in breast cancer","volume":"585","author":"Bahreyni","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156351_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102392","article-title":"Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?","volume":"106","author":"Cejalvo","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.prp.2026.156351_bib73","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1021\/acs.molpharmaceut.5c00473","article-title":"Translational Insights into Stimuli-Responsive Magnetic Nanoparticles for Breast Cancer Treatment","volume":"22","author":"Khan","year":"2025","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.prp.2026.156351_bib74","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190384","article-title":"Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus","volume":"39","author":"Yan","year":"2019","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib75","article-title":"Oncolytic adenovirus inhibits TNBC tumor growth\/metastasis in mice by targeting TGFB and overexpressing GM-CSF","volume":"33","author":"Nhan","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156351_bib76","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-20-3313","article-title":"Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT\/RT and CNS-PNET","volume":"27","author":"Garcia-Moure","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156351_bib77","first-page":"1484","article-title":"Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells","volume":"44","author":"Czolk","year":"2019","journal-title":"Int J. Mol. Med"},{"issue":"14","key":"10.1016\/j.prp.2026.156351_bib78","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2026.156351_bib79","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-20-1565","article-title":"Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus","volume":"27","author":"Farrera-Sal","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2026.156351_bib80","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.7150\/jca.51434","article-title":"Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer","volume":"12","author":"Dai","year":"2021","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib81","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/CAD.0000000000000854","article-title":"A dual cancer-specific recombinant adenovirus suppresses the growth of liver cancer cells in vivo and in vitro","volume":"31","author":"Tian","year":"2020","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.prp.2026.156351_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124941","article-title":"Engineering an oncolytic adenoviral platform for precise delivery of antisense peptide nucleic acid to modulate PD-L1 overexpression in cancer cells","volume":"668","author":"Falanga","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2026.156351_bib83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.trsl.2024.10.003","article-title":"Apolipoprotein A1-encoding recombinant adenovirus remodels cholesterol metabolism in tumors and the tumor microenvironment to inhibit hepatocellular carcinoma","volume":"275","author":"Xu","year":"2025","journal-title":"Transl. Res"},{"key":"10.1016\/j.prp.2026.156351_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138515","article-title":"Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma","volume":"286","author":"Lu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib85","article-title":"Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer","volume":"14","author":"Zhao","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156351_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116744","article-title":"Adenovirus-mediated expression of MOAP-1, Bax and RASSF1A antagonizes chemo-drug resistance of human breast cancer cells expressing cancer stem cell markers","volume":"176","author":"Tan","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"7","key":"10.1016\/j.prp.2026.156351_bib87","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41416-024-02583-0","article-title":"Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus","volume":"130","author":"Hashimoto","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2026.156351_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1360436","article-title":"Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3beta inhibitor enhances antitumor immune response against bladder cancer","volume":"15","author":"Yoon","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2026.156351_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114300","article-title":"Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model","volume":"199","author":"Kuryk","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.prp.2026.156351_bib90","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.actbio.2024.02.044","article-title":"Tumor-targeted delivery of copper-manganese biomineralized oncolytic adenovirus for colorectal cancer immunotherapy","volume":"179","author":"Li","year":"2024","journal-title":"Acta Biomater."},{"issue":"20","key":"10.1016\/j.prp.2026.156351_bib91","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.3390\/cancers15204912","article-title":"Intranasal delivery of oncolytic adenovirus XVir-N-31 via optimized shuttle cells significantly extends survival of glioblastoma-bearing mice","volume":"15","author":"El-Ayoubi","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.prp.2026.156351_bib92","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3390\/ijms22052517","article-title":"Oncolytic adenoviruses for cancer therapy","volume":"22","author":"Tripodi","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156351_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116061","article-title":"Adeno-associated virus vector hydrogel formulations for brain cancer gene therapy applications","volume":"170","author":"S\u0142yk","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.prp.2026.156351_bib94","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib95","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.prp.2026.156351_bib96","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/v15051086","article-title":"Engineering adenoviral vectors with improved GBM selectivity","volume":"15","author":"Bates","year":"2023","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.prp.2026.156351_bib97","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.7150\/jca.51434","article-title":"Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer","volume":"12","author":"Dai","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2026.156351_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216485","article-title":"The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment","volume":"581","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.prp.2026.156351_bib99","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/ijo.2015.3045","article-title":"The antitumor effects of oncolytic adenovirus H101 against lung cancer","volume":"47","author":"Lei","year":"2015","journal-title":"Int J. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2241710","article-title":"Effective intravenous delivery of adenovirus armed with TNFalpha and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer","volume":"12","author":"Kudling","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prp.2026.156351_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674400","article-title":"Oncolytic adenovirus coding for a variant interleukin 2 (vIL-2) Cytokine re-programs the tumor microenvironment and confers enhanced tumor control","volume":"12","author":"Quixabeira","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2026.156351_bib102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fonc.2020.00229","article-title":"Chemovirotherapy of Lung Squamous Cell Carcinoma by Combining Oncolytic Adenovirus With Gemcitabine","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2026.156351_bib103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2015.10.019","article-title":"Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo","volume":"487","author":"Gomez-Gutierrez","year":"2016","journal-title":"Virology"},{"issue":"18","key":"10.1016\/j.prp.2026.156351_bib104","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/cells13181597","article-title":"Advancing lung cancer treatment with combined c-met promoter-driven oncolytic adenovirus and rapamycin","volume":"13","author":"Chen","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib105","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1038\/s41598-019-43668-8","article-title":"A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma","volume":"9","author":"Sakhawat","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156351_bib106","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13046-024-03011-0","article-title":"Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice","volume":"43","author":"Dong","year":"2024","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.prp.2026.156351_bib107","unstructured":"A. Phase I. Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer [Internet]. 2023. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06125197\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib108","unstructured":"A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors [Internet]. 2018. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03740256\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib109","unstructured":"A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour [Internet]. 2014. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02053220\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib110","unstructured":"Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) [Internet]. 2021. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05076760\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib111","unstructured":"A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA\u00ae) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE\/KEYNOTE-192) [Internet]. 2016. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02798406\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib112","unstructured":"A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-\u03b3) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I) [Internet]. 2014. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT02197169\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib113","unstructured":"Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma [Internet]. 2017. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03072134\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib114","unstructured":"A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma [Internet]. 2024. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT06693986\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib115","unstructured":"Recombinant Human Adenovirus Type 5 Combined With Hepatic Artery Infusion Chemotherapy of FOLFOX in Patients With Intrahepatic Mass-forming Cholangiocarcinoma: a Single-site, Single-arm, Prospective Study [Internet]. 2021. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT05124002\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib116","unstructured":"A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent\/Metastatic Breast Cancer and Accessible Lesions [Internet]. 2012. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT01703754\u3009."},{"key":"10.1016\/j.prp.2026.156351_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and optimization prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.prp.2026.156351_bib118","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.ymthe.2021.04.015","article-title":"Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus","volume":"29","author":"Wan","year":"2021","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.prp.2026.156351_bib119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12032-025-02641-4","article-title":"Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies","volume":"42","author":"Shah","year":"2025","journal-title":"Med Oncol."},{"issue":"01","key":"10.1016\/j.prp.2026.156351_bib120","doi-asserted-by":"crossref","DOI":"10.63147\/krjs.v4i01.124","article-title":"Advancement in gene therapy: current and future of gene therapy","volume":"4","author":"Rehman","year":"2025","journal-title":"Kashmir J. Sci."},{"issue":"13","key":"10.1016\/j.prp.2026.156351_bib121","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2026.156351_bib122","first-page":"1","article-title":"Advancements in nanoparticle-based gene delivery systems for therapeutic applications: a comprehensive review","author":"Dubey","year":"2024","journal-title":"Int. J. Newgen Res. Pharm. Healthc."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:38:26Z","timestamp":1767973106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":122,"alternative-id":["S0344033826000026"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156351","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming barriers in cancer therapy with oncolytic adenoviruses: Engineering strategies and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156351"}}